Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

医学 嵌合抗原受体 多发性骨髓瘤 肿瘤科 立场文件 汽车T细胞治疗 造血细胞 重症监护医学 免疫疗法 癌症 内科学 病理 干细胞 造血 遗传学 生物
作者
Nico Gagelmann,Anna Sureda,Silvia Montoto,John Murray,Natacha Bolaños,Michelle Kenyon,Meral Beksaç,Stefan Schönland,Patrick Hayden,Hans Scheurer,Kate Morgan,Laurent Garderet,Donal P. McLornan,Annalisa Ruggeri
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:9 (10): e786-e795 被引量:31
标识
DOI:10.1016/s2352-3026(22)00226-5
摘要

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care—a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma. Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care—a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tt发布了新的文献求助10
刚刚
幸运小鱼完成签到,获得积分10
刚刚
zhawenchang发布了新的文献求助10
1秒前
1秒前
Ava的应助被CC采纳,获得10
2秒前
大面包完成签到,获得积分10
2秒前
xxy完成签到,获得积分10
2秒前
上官若男的应助被大白采纳,获得10
3秒前
Owen的应助被可研小菜鸟采纳,获得10
3秒前
4秒前
chi2完成签到,获得积分10
4秒前
4秒前
fangzi完成签到,获得积分10
5秒前
5秒前
5秒前
yeo完成签到,获得积分10
6秒前
落寞的寒云完成签到,获得积分10
6秒前
TEXAS完成签到,获得积分10
6秒前
6秒前
bkagyin的应助被浅陌采纳,获得10
6秒前
6秒前
田様的应助被一叶知秋采纳,获得10
6秒前
陈天降低完成签到,获得积分10
7秒前
7秒前
大水桶发布了新的文献求助10
7秒前
咸鱼打滚完成签到,获得积分10
7秒前
xyc完成签到,获得积分10
9秒前
慕青的应助被鳗鱼水云采纳,获得10
9秒前
9秒前
LCFXR发布了新的文献求助10
10秒前
LL完成签到,获得积分10
10秒前
10秒前
micor发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
XialianWeng完成签到,获得积分10
11秒前
Hong发布了新的文献求助10
11秒前
zhawenchang发布了新的文献求助10
11秒前
xxy发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154161
求助须知:如何正确求助?哪些是违规求助? 9550701
关于积分的说明 21700590
捐赠科研通 7743260
什么是DOI,文献DOI怎么找? 3425651
关于科研通互助平台的介绍 2550861
邀请新用户注册赠送积分活动 2469363